Lutikizumab is a bispecific antibody against IL-1alpha and IL-1beta with a bivalent variable domain structure. By binding to IL-1alpha and IL-1beta, Lutikizumab effectively inhibits their activity and is mainly used in the field of osteoarthritis research.
Purity:
95.00%
CAS Number:
[1791411-57-8]
Target:
IL Receptor
* VAT and and shipping costs not included. Errors and price changes excepted